Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

NCT03497897 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammatory Acne

Interventions

DRUG: LYS006 20 mg
DRUG: LYS006 2 mg
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals